
Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.
Dr. Giorgio Scagliotti from the University of Turin Gives 3 Important Lung Cancer Takeaway Points
Giorgio V. Scagliotti, MD, PhD, head of the Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, explains 3 lung cancer topics that require more awareness and research to produce optimal results in the future.







